¶ PALB2 Protein (Partner and Localizer of BRCA2)
[^1]
[^2]
[@rahmad2011]
[^3]
[@rahmad2011]
[^2]
[^3]
[^4]
[^5]
| PALB2 Protein |
|---|
| Protein Name | Partner and Localizer of BRCA2 |
| Gene Symbol | [PALB2](/genes/palb2) |
| UniProt ID | [Q86VC1](https://www.uniprot.org/uniprot/Q86VC1) |
| Chromosomal Location | 16p12.2 |
| Protein Length | 1186 amino acids |
| Molecular Weight | ~130 kDa |
| Subcellular Localization | Nucleus, chromatin |
| Protein Family | DNA repair, Fanconi anemia pathway |
PALB2 (Partner and Localizer of BRCA2) is a critical DNA repair protein that serves as a molecular scaffold linking the BRCA1 and BRCA2 pathways in homologous recombination repair . Originally identified as a binding partner of BRCA2, PALB2 plays essential roles in maintaining genome stability through its involvement in DNA double-strand break repair, replication fork protection, and the Fanconi anemia pathway .
Beyond its well-established role in cancer predisposition, emerging research has revealed important connections between PALB2 dysfunction and neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS) . The protein's functions in DNA repair are particularly crucial in post-mitotic neurons, which cannot rely on cell division to eliminate DNA-damaged cells and must maintain genomic integrity throughout the lifespan.
Germline PALB2 mutations are associated with a significantly increased risk of breast cancer, pancreatic cancer, and ovarian cancer, with an estimated 2-4-fold increased risk compared to the general population . Additionally, PALB2 is classified as a Fanconi anemia complementation group F (FANC-F) gene, and biallelic mutations cause a severe FA phenotype with developmental abnormalities, bone marrow failure, and cancer predisposition .
PALB2 serves as a critical hub in the DNA damage response network, coordinating the activities of multiple DNA repair proteins :
- BRCA2 recruitment: PALB2 directly binds to BRCA2 through its WD40 domain, facilitating BRCA2 recruitment to sites of DNA damage
- RAD51 loading: PALB2 helps load RAD51 onto single-stranded DNA covered by RPA, enabling strand invasion during homologous recombination
- Checkpoint coordination: PALB2 interacts with ATM and other checkpoint kinases to ensure proper cell cycle arrest during DNA repair
¶ Domain Structure and Biochemistry
PALB2 contains several functional domains:
- N-terminal domain (1-300 aa): Chromatin binding and BRCA1 interaction
- Coiled-coil domain (300-400 aa): BRCA2 binding
- WD40 repeat domain (400-800 aa): Protein-protein interactions
- C-terminal region (800-1186 aa): RAD51 interaction and nuclear localization
The protein forms a homodimer or multimer that provides multiple binding surfaces for interaction partners.
PALB2 is an essential component of the Fanconi anemia pathway :
- DNA damage detection: FA pathway senses DNA interstrand crosslinks (ICLs)
- Complex assembly: PALB2 is recruited to damaged sites as part of the FA core complex
- Repair coordination: PALB2 facilitates downstream repair through BRCA2 and RAD51
- Checkpoint activation: FA pathway coordinates cell cycle arrest with repair
Recent studies have revealed additional roles for PALB2 in replication fork stability :
- Fork regression: PALB2 helps regress stalled replication forks
- Fork remodeling: Facilitates template switching during repair
- ** nucleases protection**: Prevents excessive nucleolytic degradation of stalled forks
| Cancer Type |
Risk Level |
Notes |
| Breast cancer |
2-4x increased |
High penetrance with family history |
| Pancreatic cancer |
3-6x increased |
Especially in familial cases |
| Ovarian cancer |
2-3x increased |
Less pronounced than BRCA1/2 |
| Prostate cancer |
Moderate increase |
Emerging evidence |
Over 300 pathogenic variants have been identified in PALB2, including:
- Missense mutations (primarily in WD40 domain)
- Nonsense mutations and frameshifts
- Splice site mutations
- Large genomic rearrangements
The WD40 domain mutations often retain partial function, leading to intermediate cancer risk, while truncating mutations confer higher risk.
Emerging evidence links PALB2 dysfunction to AD pathogenesis :
-
DNA repair impairment:
- Reduced PALB2 expression in AD brain tissue
- Impaired homologous recombination in neurons
- Accumulation of DNA damage with age
-
Genomic instability:
- Increased mutation burden in AD neurons
- Chromosomal abnormalities in AD brain
- Telomere dysfunction
-
Amyloid interaction:
- Aβ peptides can inhibit PALB2 function
- PALB2 deficiency exacerbates Aβ toxicity
- Therapeutic potential for enhancement
-
Therapeutic implications:
- PARP inhibitors show benefit in AD models
- Gene therapy approaches under investigation
- Small molecule activators in development
PALB2 may play protective roles in PD through several mechanisms :
-
Mitochondrial DNA repair:
- PALB2 contributes to mtDNA repair
- Protecting against mitochondrial dysfunction
- Supporting dopaminergic neuron survival
-
Oxidative stress response:
- ROS-induced DNA damage accumulation
- Impaired repair capacity in PD brain
- Interaction with PINK1/PARKIN pathway
-
Alpha-synuclein connection:
- DNA damage can trigger α-synuclein aggregation
- PALB2 deficiency may promote aggregation
- Synuclein pathology linked to genome instability
Recent studies reveal connections between PALB2 and ALS :
-
Genomic instability in ALS:
- Elevated DNA damage in ALS motor neurons
- Mutations in DNA repair genes in ALS patients
- C9orf72 repeat expansions affect DNA repair
-
PARP activation:
- Excessive PARP activation in ALS
- NAD+ depletion through poly(ADP-ribosyl)ation
- PALB2 dysfunction exacerbates this pathway
-
TDP-43 pathology:
- TDP-43 inclusions in ALS neurons
- DNA damage promotes TDP-43 mislocalization
- PALB2 may protect against this process
Biallelic PALB2 mutations cause Fanconi anemia type F :
- Clinical features: Congenital abnormalities, bone marrow failure, cancer predisposition
- Cellular phenotype: Hypersensitivity to DNA crosslinking agents
- Molecular defect: Complete loss of homologous recombination capacity
PALB2 operates through multiple molecular mechanisms :
-
Initiation:
- DNA double-strand breaks recognized by MRN complex
- ATM activation and checkpoint signaling
- CtIP-mediated end resection
-
PALB2-mediated recruitment:
- PALB2 binds to BRCA1 through N-terminal domain
- PALB2 recruits BRCA2 to damage sites
- RAD51 loading onto ssDNA
-
Strand invasion and resolution:
- RAD51 filament formation
- D-loop formation
- DNA synthesis and ligation
-
ICL detection:
- FA core complex recognizes crosslinks
- ATR/ATM activation
- Checkpoint arrest
-
Unhooking and repair:
- PALB2 coordinates NER and HR
- Replication restart mechanisms
- Completion of repair
In neurons, PALB2 provides neuroprotection through [@te02021]:
-
Genomic stability maintenance:
- Preventing mutation accumulation
- Protecting telomere integrity
- Maintaining neuronal identity
-
Cellular stress response:
- Oxidative DNA damage repair
- Mitochondrial DNA repair
- Metabolic stress adaptation
-
Aging protection:
- Counteracting age-related DNA damage
- Supporting neuron survival
- Preventing senescence
| Approach |
Description |
Status |
| PARP inhibitors |
Synthetic lethality in PALB2-deficient tumors |
Approved (olaparib) |
| Radiotherapy |
Enhanced sensitivity in PALB2-mutant cells |
Clinical trials |
| Combination therapy |
PARP + checkpoint inhibitors |
Phase II/III |
| Gene therapy |
PALB2 restoration approaches |
Preclinical |
PALB2-deficient tumors are highly sensitive to PARP inhibition :
- Synthetic lethality through replication stress
- Accumulation of single-strand breaks
- Crisis under replication stress
- Clinical responses in PALB2 carriers
Resistance to PARP inhibitors can develop through:
- BRCA2 restoration
- RAD51 upregulation
- Loss of PARP expression
- DNA repair pathway switches
-
PARP inhibition:
- Low-dose PARP inhibition may protect neurons
- Reducing NAD+ depletion
- Maintaining DNA repair capacity
-
Gene therapy:
- AAV-mediated PALB2 delivery
- Neuron-specific promoters
- BBB-penetrating vectors
-
Small molecule approaches:
- PALB2 expression enhancers
- DNA repair modulators
- Metabolic cofactors (NAD+ precursors)
-
Mitochondrial protection:
- Enhancing mtDNA repair
- Supporting dopaminergic neurons
- Mitochondrial biogenesis activation
-
Antioxidant approaches:
- Reducing oxidative DNA damage
- Enhancing base excision repair
- Mitochondrial-targeted antioxidants
Several trials are investigating PALB2-related therapies:
- Olaparib in PALB2-mutant breast cancer (NCT01905592)
- Rucaparib in PALB2-associated pancreatic cancer (NCT03140670)
- Novel PARP inhibitors in solid tumors (multiple trials)
- NAD+ precursors in AD (NCT03067051)
Key research areas include:
- Understanding PALB2 regulation: Epigenetic control, post-translational modifications
- Developing neuroprotective strategies: Gene therapy, small molecule activators
- Biomarker development: DNA damage markers, circulating tumor DNA
- Resistance mechanisms: Identifying and overcoming PARP inhibitor resistance
- FA gene therapy: Viral vector approaches for FA patients
- Palb2 knockout mice: Embryonic lethal
- Conditional knockout: Tissue-specific deletion models
- Knock-in models: Patient mutations in mice
- Palb2 morphants show developmental defects
- DNA damage response impaired
- Cancer predisposition models
- Human iPSC-derived neurons
- Organoid systems
- 3D culture models
- Fong et al., PALB2 mutation and cancer risk: Clinical implications. J Natl Cancer Inst. 2010
- Rahman et al., PALB2 mutations in breast and pancreatic cancer. Nat Genet. 2011
- Mallery et al., Structural basis for PALB2-BRCA2 interaction. Mol Cell. 2010
- Antoniou et al., PALB2 and cancer predisposition: Updated meta-analysis. J Med Genet. 2014
- Park et al., PALB2 in DNA repair and neurodegeneration. Cell Mol Neurobiol. 2017
- Wang et al., PALB2 in homologous recombination repair. Cell Stem Cell. 2017
- Huang et al., PALB2 and Fanconi anemia pathway. Blood. 2019
- Zhang et al., DNA damage response in neurons: PALB2 perspective. Aging Cell. 2019
- Scheckel et al., Genomic instability in ALS: PALB2 connections. Brain. 2020
- Teo et al., DNA repair defects in neurodegenerative diseases. Nat Rev Neurol. 2021